Shopping Cart
- Remove All
Your shopping cart is currently empty
(87)
NF-κBRANKL/RANK
Receptor activator of nuclear factor kappa-Β ligand (RANKL) is a protein that in humans is encoded by the TNFSF11 gene. Receptor activator of nuclear factor κ B (RANK) is the receptor for RANKL. RANKL/RANK is associated with bone remodeling and repair, immune cell function, lymph node development, thermal regulation, and mammary gland development. Osteoprotegerin (OPG) is a decoy receptor for RANKL, and regulates the stimulation of the RANK signaling pathway by competing for RANKL. The cytoplasmic domain of RANK binds TRAFs 1, 2, 3, 5, and 6 which transmit signals to downstream targets such as NF-κB and JNK.
Denosumab
T9917615258-40-7
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
- $178
Size
QTY
Cyanidin Chloride
T5528528-58-5
Cyanidin Chloride, the main phenolic antioxidant in the grape (Vitis vinifera), in particular in the liposomal forms, could be used for treatment of diabetes mellitus complications.
- $30
Size
QTY
Amakusamine
T730612923661-84-9In house
Amakusamine is an indole alkaloid from the sponge of Psammocinia sp. It inhibits RANKL-induced isolation of multinucleated osteoclasts and inhibits RANKL-induced multinucleated osteoclasts.
- $293
Size
QTY
Alisol B
T577018649-93-9
Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis.
- $64
Size
QTY
NFATc1-IN-1
T615311912422-56-0
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
- $47
Size
QTY
(2S)-2'-Methoxykurarinone
TN1215270249-38-2
(2S)-2'-Methoxykurarinone is isolated from the roots of Sophora flavescens. (2S)-2'-Methoxykurarinone has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone displays cytotoxic activity against human myeloid leukemia HL-60 cells.
- $58
Size
QTY
Boldine
T5720476-70-0
Boldine (1,10-Dimethoxy-2,9-dihydroxyaporphine) is a natual product .Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities.
- $35
Size
QTY
10-Hydroxydecanoic Acid
TMO26851679-53-4
10-Hydroxydecanoic Acid (NSC 15139) has antibacterial, anti - cancer and anti - radiation activity.
- $30
Size
QTY
2,3-Bis(3-indolylmethyl)indole
T38799138250-72-3
2,3-Bis(3-indolylmethyl)indole exhibits a concentration-dependent inhibition of RANKL-induced osteoclastogenesis, actin ring formation, and bone resorption.
Inquiry
1,3-Dibenzyl-5-fluorouracil
T8849475500-02-6
1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor that suppresses the formation of osteoclasts, functioning by downregulating the signaling pathways of nuclear factor κB ligand receptor activator (Receptor activator of NF-κB ligand, RANKL) and macrophage colony-stimulating factor (M-CSF). This compound is used in the research of metabolic bone diseases.
- $1,520
Size
QTY
SPA0355
T2047111251839-15-2
SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.
- Inquiry Price
Size
QTY
AS2690168 hydrochloride
T2048131393899-47-2
AS2690168 hydrochloride is an orally active inhibitor of RANKL signaling that can suppress RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.
- Inquiry Price
Size
QTY
Anti-osteoporosis agent-11
T2006502869099-50-1
Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.
- $1,520
Size
QTY
AS2690168 (free base)
T2041371393999-78-4
AS2690168 freebase is an orally active inhibitor of RANKL signaling, capable of suppressing RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.
- Inquiry Price
Size
QTY
Narlumosbart
T806182646587-68-8
Narlumosbart (JMT103) is an IgG4κ monoclonal antibody that selectively binds to the receptor activator of nuclear factor-κB ligand (RANKL)[1].
- Inquiry Price
Size
QTY
Go to page 1
Page of 1
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.